Who Paid My Doc
Lee Mandel
Plastic Surgery within the Head & Neck Hollywood, FL Medical Doctor
NPI 1851326029 CMS profile 83647
4400 Sheridan St, Ste 240, Hollywood, FL 33021
General payments
$69,390
Research payments
$0
Ownership & investment interest
$0
Research they led as principal investigator
$31,072
Through program year 2025, Lee Mandel of Hollywood, FL is reported in the CMS Open Payments database as having received $69,390 across 51 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $31,072 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 97th percentile of Plastic Surgery within the Head & Neck profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
6 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $223 | 3 | |
| 2024 | General | $29 | 1 | |
| 2022 | General | $10,942 | 2 | |
| 2021 | General | $14,456 | 9 | |
| 2020 | General | $4,535 | 8 | |
| 2019 | General | $39,205 | 28 |
Beside peers
- Lee Mandel
- Plastic Surgery within the Head & Neck median
- Middle half of Plastic Surgery within the Head & Neck
- National median
In program year 2025, general payments to Lee Mandel were reported at $223. Among 399 Plastic Surgery within the Head & Neck profiles paid that year, the median was $237 and the middle half received between $103 and $520.
Show as a table
| Year | Lee Mandel | Plastic Surgery within the Head & Neck median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $39,205 | $200 | $82–$550 | $163 |
| 2020 | $4,535 | $120 | $46–$330 | $114 |
| 2021 | $14,456 | $166 | $60–$382 | $132 |
| 2022 | $10,942 | $208 | $83–$530 | $149 |
| 2023 | $0 | $202 | $77–$538 | $160 |
| 2024 | $29 | $260 | $99–$645 | $164 |
| 2025 | $223 | $237 | $103–$520 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 13 drugsPart D claims
608
Drug cost
$4,644
Branded share of claims
22.7%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Azelastine-Fluticasone Azelastine/Fluticasone | Brand | 15 | $1,974 | |
| Azelastine Hcl | Generic | 36 | $636 | |
| Amoxicillin-Clavulanate Potass Amoxicillin/Potassium Clav | Brand | 54 | $323 | |
| Ipratropium Bromide | Generic | 12 | $321 | |
| Atorvastatin Calcium | Generic | 12 | $267 | |
| Prednisone | Generic | 126 | $217 | |
| Omeprazole | Generic | 13 | $191 | |
| Doxycycline Hyclate | Generic | 25 | $167 | |
| Fluticasone Propionate | Generic | 20 | $149 | |
| Sulfamethoxazole-Trimethoprim Sulfamethoxazole/Trimethoprim | Brand | 57 | $149 |
The 10 drugs with the highest cost, of 13 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 9,296 Part D prescribers listed as Otolaryngology; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 46 billing codesPaid by Medicare
$434,116
Medicare patients
200
Services billed
5,896
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 73% | |
| Arthritis | 51% | |
| Ischemic heart disease | 39% | |
| Depression | 24% | |
| Diabetes | 21% | |
| Atrial fibrillation | 17% | |
| Chronic kidney disease | 16% | |
| Cancer | 15% |
| Drug given in the clinic | Where | Patients | Services | Paid by Medicare |
|---|---|---|---|---|
| Injection, acetaminophen, not otherwise specified,10 mg J0131 | Office | 11 | 1,100 | $35 |
| Injection, glycopyrrolate, 0.1 mg J1596 | Office | 11 | 22 | $9 |
| Injection, ondansetron hydrochloride, per 1 mg J2405 | Office | 11 | 44 | $3 |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
51 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Plastic Surgery within the Head & Neck in Florida
Kavita Pattani
Plastic Surgery within the Head & Neck · Orlando, FL
Francisco Civantos
Plastic Surgery within the Head & Neck · Miami, FL
Shaun Baker
Plastic Surgery within the Head & Neck · Sarasota, FL
Eric Wu
Plastic Surgery within the Head & Neck · Ocoee, FL
Brian Moore
Plastic Surgery within the Head & Neck · Eglin Afb, FL
Scott Trimas
Plastic Surgery within the Head & Neck · Jacksonville, FL
Related records
Plastic Surgery within the Head & Neck in Florida
Practitioners in the same specialty and state, ranked by reported value.
All Plastic Surgery within the Head & Neck
Everyone recorded under this specialty, nationwide.
Doctors in Florida
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.